TRANSDERMAL HRT RELIEVING POSTMENOPAUSAL SYMPTOMS

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

January 31, 2004

Study Completion Date

April 30, 2008

Conditions
Menopause
Interventions
DRUG

Transdermal Hormone Replacement Therapy

"The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal progesterone was prescribed. The patients were evaluated 3 months after THRT treatment protocol.~All the patients were instructed about how to use the progesterone pump for transdermal application, performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."

DRUG

Transdermal Nanoformulation

The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.

DRUG

Transdermal formulation

66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.

Trial Locations (1)

60115-191

Gynelogical Center, Fortaleza

All Listed Sponsors
collaborator

Universidade Federal de Sergipe

OTHER

lead

University Potiguar

OTHER

NCT02033512 - TRANSDERMAL HRT RELIEVING POSTMENOPAUSAL SYMPTOMS | Biotech Hunter | Biotech Hunter